Daily Clinical Briefing · Educational reading for healthcare professionals
VASSPR's neutral result needs scrutiny of actual treatment differences before changing vasopressin protocols.
When sodium falls during vasopressin treatment, review whether the infusion remains necessary; its antidiuretic activity can contribute even without severe hyponatraemia.
Starting vasopressin earlier in septic shock has an appealing rationale: reduce catecholamine requirements before norepinephrine doses climb further. Whether that translates into better survival is a separate question.
VASSPR compared hospital-level strategies for starting vasopressin at lower or higher norepinephrine-equivalent thresholds, with monthly crossover between strategies. Both used vasopressin at 0.03 units/min. The planned initiation thresholds were 0.1 and 0.4 micrograms/kg/min, although clinicians retained discretion over when to start treatment.
At 28 days, mortality was 31.8% with the lower-threshold strategy and 33% with the higher threshold. The primary adjusted analysis gave a P value of 0.62. There was also no demonstrated advantage in kidney replacement therapy-free days.
These findings do not establish a survival benefit from routine earlier initiation. They also leave uncertainty: a neutral result does not prove identical effects. Choosing the most favourable boundary of a confidence interval and presenting it as the treatment benefit would overstate what the trial found.
The planned thresholds suggest a substantial difference in practice. For a 100 kg adult, they correspond to norepinephrine-equivalent rates of 10 and 40 micrograms/min. But the treatment actually delivered was less clearly separated.
Vasopressin was given to 68% of the lower-threshold group and 42.7% of the higher-threshold group. Among recipients, median initiation doses were 0.14 and 0.34 micrograms/kg/min, closer together than the intended thresholds.
About one quarter of participants never reached 0.07 micrograms/kg/min, below either planned trigger. Their inclusion adds patients for whom the assigned strategies may produce little or no treatment difference. Clinician discretion further narrows the comparison.
This helps explain why a pragmatic strategy trial may find less separation than its protocol suggests. It does not establish that a benefit would appear with stricter adherence, nor justify treating all patients who received no vasopressin as equivalent across groups.
Vasopressin can spare catecholamines, and blood pressure provides an immediately visible response. Neither observation is sufficient evidence of improved survival. The decision about timing remains uncertain rather than being settled by an attractive physiological effect.
The discussion also reports lower sodium with earlier vasopressin use, despite similar rates of severe hyponatraemia. Vasopressin's antidiuretic activity therefore remains relevant when sodium falls during treatment.
For a unit reviewing its protocol, VASSPR supports examining the threshold clinicians actually use before claiming that routine earlier initiation saves lives. For an individual patient whose sodium is falling, it supports reviewing the continuing need for vasopressin rather than overlooking a possible treatment effect.

Starting vasopressin at a lower norepinephrine-equivalent threshold in septic shock shows no demonstrated survival advantage in VASSPR; limited treatment separation complicates interpretation, while catecholamine sparing and falling sodium need to be considered separately from mortality.

In older adults with acute optic neuropathy, pain history, early optical coherence tomography, visual fields and the unaffected optic disc help distinguish inflammatory from ischaemic disease; headache and disc oedema alone cannot reliably separate them.

Rare human glanders can cause skin, lymphatic and internal-organ abscesses or severe pneumonia; animal-contact and laboratory histories, delayed culture growth and the possibility of relapse shape recognition and the prolonged treatment described.
When reviewing a vasopressin-start protocol, compare actual initiation doses with intended thresholds and check how many patients never reach either trigger. Describe any reduction in catecholamine requirements as a physiological effect, without presenting it as evidence of improved survival.
A critical care team considers routine earlier vasopressin for septic shock after a trial reports 28-day mortality of 31.8% with a lower initiation threshold and 33% with a higher threshold. The primary adjusted analysis gives a P value of 0.62. What conclusion should guide the protocol review?
The trial does not demonstrate a mortality benefit from lower-threshold initiation, but uncertainty remains; the result does not prove identical effects. The team should also examine actual treatment separation, including initiation doses and the proportion of patients who never reach either threshold.
An older adult has acute unilateral optic neuropathy with marked disc oedema and an altitudinal visual field defect. Swelling obscures the affected optic disc's underlying anatomy. Which finding in the other eye would strengthen the case for non-arteritic anterior ischaemic optic neuropathy?
A crowded optic disc with a small cup-to-disc ratio in the unaffected eye supports a disc-at-risk anatomy. Examining that eye helps when oedema obscures the affected disc, while the altitudinal field defect provides another clue to an ischaemic cause.
An adult develops fever and a painful hand abscess after close occupational contact with horses. Glanders is suspected, but culture shows no growth at 24 hours. How should this result affect the assessment?
An absence of growth at 24 hours does not exclude glanders because the organism takes at least 48 hours to grow in culture. Interpret the result alongside the exposure history and clinical pattern; that minimum interval does not guarantee a definitive result at 48 hours.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.